Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 9/20 | 0.61 |
| ▸ | MAPK10 | P53779 | 8/20 | 0.61 |
| ▸ | MAPK9 | P45984 | 6/20 | 0.61 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.43 |
| ▸ | CDK2 | P24941 | 6/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16802604 | 0.83 | MAPK8 (0.60) | MAPK8MAPK10MAPK9CDK2CDK4 | |
| SCHEMBL16799595 | 0.79 | MAPK8 (0.65) | MAPK8MAPK10MAPK9CCNE1CDK2 | |
| SCHEMBL18148268 | 0.77 | MAPK8 (1.00) | MAPK8MAPK10MAPK9CDK2 | |
| SCHEMBL16802603 | 0.77 | MAPK8 (1.00) | MAPK8MAPK10MAPK9CDK2 | |
| SCHEMBL16802653 | 0.76 | MAPK8 (1.00) | MAPK8MAPK10MAPK9CCNE1CDK2 | |
| SCHEMBL16802598 | 0.74 | MAPK8 (0.65) | MAPK8MAPK10MAPK9CDK2ROCK2 | |
| SCHEMBL18148272 | 0.74 | MAPK8 (0.65) | MAPK8MAPK10MAPK9CDK2ROCK2 | |
| SCHEMBL18148252 | 0.74 | MAPK8 (0.76) | MAPK8MAPK10MAPK9CCNT1CDK9 | |
| SCHEMBL16802600 | 0.74 | MAPK8 (0.76) | MAPK8MAPK10MAPK9CCNT1CDK9 | |
| SCHEMBL16799912 | 0.74 | MAPK8 (0.72) | MAPK8MAPK10CDK2HPGDSCDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304466-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2016-10-20 | — | — | US | disclosed |
| US-20160304466-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2016-10-20 | — | — | US | disclosed |
| US-20160304466-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2016-10-20 | — | — | US | disclosed |
| WO-2015084936-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304466-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | MAPK3, MAP3K3, MAP3K2 | MAPK8 55/4885MAPK10 31/4885MAPK9 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.